

Agencia Española de Medicamentos y Productos Sanitarios

C/Campezo 1, Edificio 8
28022 – Madrid
España
(Reference Member State)

DECENTRALISED PROCEDURE

FINAL PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

TULLAVIS 25 mg/ml SOLUTION FOR INJECTION FOR PIGS

CORREO ELECTRÓNICO

mresvet@aemps.es

14971 Final PuAR_ES_V_0359_001_DC_Tulavis-25_07 06 23.docx

F-DMV-25-06

C/ CAMPEZO, 1 – EDIFICIO 8
28022 MADRID
TEL: 91 822 54 01
FAX: 91 822 5443



MODULE 1

PRODUCT SUMMARY

EU Procedure number	ES/V/0359/001/DC
Name, strength and pharmaceutical form	Tullavis 25 mg/ml solution for injection for pigs
Applicant	LIVISTO Int'l, S.L. Av. Universitat Autònoma, 29 08290 Cerdanyola del Vallès (Barcelona), Spain
Active substance(s)	Tulathromycin
ATC Vetcode	QJ01FA94
Target species	Pigs
Indication for use	Treatment and metaphylaxis of swine respiratory disease (SRD) associated with <i>Actinobacillus pleuropneumoniae</i> , <i>Pasteurella multocida</i> , <i>Mycoplasma hyopneumoniae</i> , <i>Haemophilus parasuis</i> and <i>Bordetella bronchiseptica</i> susceptible to tulathromycin.



MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies website (<http://www.hma.eu>).



MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Decentralised application in accordance with Article 13 (1) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	29/07/2020
Date product first authorised in the ReferenceMemberState (MRP only)	-
Concerned Member States for original procedure	AT, BE, BG, CY, CZ, DE, DK, EE, EL, FI, FR, HU, HR, IE, IT, LT, LV, NL, PL, PT, RO, SI, SK, UK

I. SCIENTIFIC OVERVIEW

For public assessment reports for the first authorisation in a range:

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. *Qualitative and quantitative particulars*

The product contains tulathromycin (25 mg/ml) as active substance, monothioglycerol as antioxidant and the excipients citric acid anhydrous, propylene glycol, hydrochloric acid solution (10%), sodium hydroxide and water for injections. The product is a clear, colourless to yellowish solution.

The veterinary medicinal product is presented in clear glass (type II Ph. Eur.) vials of 50 ml, 100 ml and 250 ml closed with a bromobutyl rubber stopper and sealed with an aluminium cap.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. *Method of Preparation of the Product*

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. *Control of Starting Materials*

The active substance is tulathromycin, an established active substance which is not described in a pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

The information on the active substance is provided according to the Active Substance Master File (ASMF) procedure.

Satisfactory TSE information has been provided in compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products.

D. *Control on intermediate products*

Not applicable



E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production sites have been provided demonstrating compliance with the specification.

F. Stability

Stability data on the active substance tulathromycin have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life (3 years) when stored under the approved conditions.

Data submitted on in-use stability studies are considered sufficient to support an in-use shelf life of 28 days after broaching.

G. Other Information

Not applicable.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACOTOXICOLOGICAL) (for pharmaceuticals only)

III.A Safety Testing

Pharmacological Studies

As this is a generic application according to Article 13 and bioequivalence with the reference product has been demonstrated, results of pharmacological tests are not required.

The pharmacological aspects of this product are identical to the reference product.

Toxicological Studies

As this is a generic application according to Article 13 and bioequivalence with the reference product has been demonstrated, results of toxicological tests are not required.

The toxicological aspects of this product are identical to the reference product.

User Safety

Although this is a generic application according to Article 13 and bioequivalence with the reference product has been demonstrated, the applicant has provided a brief user safety assessment broadly in accordance with the relevant guideline.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines.

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because in all scenarios the initial predicted environmental concentrations in soil is less than 100 µg/kg.

III.B Residues documentation

Residue Studies

No residue depletion studies were conducted because bioequivalence to the reference product has been demonstrated and there are no differences in the composition of the candidate product when compared to the reference product.



MRLs

The active substance Tulathromycin is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010.

MRLs are listed below:

	Porcine
Muscle	800 µg/kg
Liver	4000 µg/kg
Kidney	8000 µg/kg
Fat / skin	300 µg/kg
Milk	Not for use in animals from which milk is produced for human consumption.

Withdrawal Periods

Based on the data provided above, a withdrawal period of 13 days for meat and offal in pigs are justified.

IV. CLINICAL ASSESSMENT (EFFICACY)

IV.A Pre-Clinical Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

IV.B Clinical Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.



V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

Quality changes

Summary of change (Application number)	Section updated in Module 3	Approval date
F.II.e.5.b - QUALITY CHANGES - Finished product - Container closure system - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products Scope: To introduce an additional 50 ml vial (committed during the registration process of the VMP).	N/A	07/06/2023